ICARES Medicus (ROCO:6612) Beneish M-Score: -1.94 (As of Jun. 29, 2026)


ROCO:6612 ICARES Medicus Inc ROCO:6612
84 GF Score
Price NT$71.60
GF Value NT$188.59
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is ICARES Medicus Beneish M-Score?

ICARES Medicus ROCO:6612 +1.13% 84 Beneish M-Score is -1.94 as of Jun. 29, 2026. GuruFocus rates ROCO:6612 with a GF Score™ of 84/100 and a GF Value™ of NT$188.59 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 765 Medical Devices & Instruments companies, ICARES Medicus ranks worse than 82.48% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -1.94 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for ICARES Medicus's Beneish M-Score or its related term are showing as below:

ROCO:6612' s Beneish M-Score Range Over the Past 10 Years
Min: -2.49   Med: -2.18   Max: -1.44
Current: -1.94

During the past 13 years, the highest Beneish M-Score of ICARES Medicus was -1.44. The lowest was -2.49. And the median was -2.18.


ICARES Medicus Beneish M-Score Historical Data

* Premium members only.

The historical data trend for ICARES Medicus's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ICARES Medicus Beneish M-Score Chart

ICARES Medicus Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.22 -2.04 -2.18 -1.93 -1.94

ICARES Medicus Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.93 -1.49 -1.27 -2.13 -1.94

ROCO:6612 vs ISRG, BDX, MDLN: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, ICARES Medicus's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ICARES Medicus Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ICARES Medicus's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where ICARES Medicus's Beneish M-Score falls into.


ROCO:6612
84GF Score
ICARES Medicus Inc ROCO:6612
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ICARES Medicus Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of ICARES Medicus for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1119+0.528 * 1.1807+0.404 * 0.8063+0.892 * 1.3154+0.115 * 0.7094
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0415+4.679 * 0.034611-0.327 * 0.9582
=-1.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$375 Mil.
Revenue was 300.561 + 263.579 + 269.197 + 297.649 = NT$1,131 Mil.
Gross Profit was 190.538 + 145.005 + 160.364 + 172.27 = NT$668 Mil.
Total Current Assets was NT$1,701 Mil.
Total Assets was NT$3,180 Mil.
Property, Plant and Equipment(Net PPE) was NT$527 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$150 Mil.
Selling, General, & Admin. Expense(SGA) was NT$381 Mil.
Total Current Liabilities was NT$833 Mil.
Long-Term Debt & Capital Lease Obligation was NT$230 Mil.
Net Income was 18.552 + 2.372 + -17.024 + 47.331 = NT$51 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0 Mil.
Cash Flow from Operations was -4.612 + -78.579 + 111.219 + -86.861 = NT$-59 Mil.
Total Receivables was NT$256 Mil.
Revenue was 256.9 + 256.953 + 184.939 + 161.001 = NT$860 Mil.
Gross Profit was 172.821 + 159.832 + 135.738 + 131.338 = NT$600 Mil.
Total Current Assets was NT$1,413 Mil.
Total Assets was NT$3,008 Mil.
Property, Plant and Equipment(Net PPE) was NT$478 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$89 Mil.
Selling, General, & Admin. Expense(SGA) was NT$278 Mil.
Total Current Liabilities was NT$574 Mil.
Long-Term Debt & Capital Lease Obligation was NT$476 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(374.523 / 1130.986) / (256.076 / 859.793)
=0.331147 / 0.297834
=1.1119

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(599.729 / 859.793) / (668.177 / 1130.986)
=0.697527 / 0.590792
=1.1807

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1701.336 + 526.53) / 3179.996) / (1 - (1413.326 + 477.811) / 3008.195)
=0.299412 / 0.371338
=0.8063

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1130.986 / 859.793
=1.3154

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(89.044 / (89.044 + 477.811)) / (149.757 / (149.757 + 526.53))
=0.157084 / 0.22144
=0.7094

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(380.818 / 1130.986) / (277.97 / 859.793)
=0.336713 / 0.323299
=1.0415

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((229.681 + 833.459) / 3179.996) / ((475.721 + 573.803) / 3008.195)
=0.334321 / 0.348888
=0.9582

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(51.231 - 0 - -58.833) / 3179.996
=0.034611

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

ICARES Medicus has a M-score of -1.94 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.94 mean?
ICARES Medicus (ROCO:6612) has a Beneish M-Score of -1.94 as of Jun. 29, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on ICARES Medicus and its competitors. According to the industry distribution chart, ICARES Medicus ranks #631 out of 765 companies in the Medical Devices & Instruments industry, placing it in the top 82.5%.
Is ICARES Medicus' Beneish M-Score too high?
ICARES Medicus' current Beneish M-Score is -1.94. Based on the distribution chart, ICARES Medicus ranks #631 out of 765 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ICARES Medicus has a GF Score™ of 84/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ICARES Medicus' Beneish M-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, ICARES Medicus ranks #631 out of 765 companies for Beneish M-Score. This places ICARES Medicus in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on ICARES Medicus and its competitors. ICARES Medicus's current Beneish M-Score is -1.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICARES Medicus stock overvalued right now?
Based on GuruFocus' analysis, ICARES Medicus (ROCO:6612) is currently considered Possible Value Trap. The stock's GF Value™ is NT$188.59, compared to a current price of NT$71.60 — trading 62% below its estimated fair value. The current Beneish M-Score is -1.94. ICARES Medicus' overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For ICARES Medicus (ROCO:6612), the current Beneish M-Score is -1.94 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ICARES Medicus (ROCO:6612) Overvalued in 2026?

Based on GuruFocus' analysis, ICARES Medicus stock appears to be undervalued. The current stock price of NT$71.60 is trading 62% below its estimated GF Value™ of NT$188.59. GuruFocus considers ICARES Medicus to be Possible Value Trap.

Key valuation signals for ROCO:6612:

  • Beneish M-Score: -1.94
  • GF Value™: NT$188.59 vs. price of NT$71.60 (62% below fair value)
  • GF Score™: 84/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6612 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ICARES Medicus Business Description

Address Section 2, Shengyi Road, No. 16, 4th Floor, Hsinchu County, Zhubei, TWN, 30261
ICARES Medicus Inc is engaged in providing high-grade nanomedical lubricious coatings and various surface treatments for implantable or interventional medical devices. In addition, it also designs, develops, manufactures, and sells intraocular lenses and nanomedical devices. The company's operating segments are Europe and America, which derive maximum revenue, China, and R.O.C. Geographically, it generates maximum revenue from the United States, followed by Taiwan, Spain, England, Japan, China, Germany, and other countries.
84GF Score

Get the complete analysis for ROCO:6612

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$71.60
Price
NT$188.59
GF Value